Allogene Therapeutics (ALLO) Payables: 2019-2025
Historic Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $3.7 million.
- Allogene Therapeutics' Payables fell 32.82% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 36.91%. This contributed to the annual value of $5.4 million for FY2024, which is 8.53% down from last year.
- Per Allogene Therapeutics' latest filing, its Payables stood at $3.7 million for Q3 2025, which was down 23.75% from $4.9 million recorded in Q2 2025.
- Allogene Therapeutics' Payables' 5-year high stood at $14.9 million during Q1 2021, with a 5-year trough of $3.7 million in Q3 2025.
- Moreover, its 3-year median value for Payables was $5.8 million (2024), whereas its average is $7.3 million.
- In the last 5 years, Allogene Therapeutics' Payables surged by 106.63% in 2021 and then crashed by 62.50% in 2025.
- Quarterly analysis of 5 years shows Allogene Therapeutics' Payables stood at $10.3 million in 2021, then spiked by 35.45% to $13.9 million in 2022, then tumbled by 57.54% to $5.9 million in 2023, then declined by 8.53% to $5.4 million in 2024, then slumped by 32.82% to $3.7 million in 2025.
- Its Payables stands at $3.7 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.1 million for Q1 2025.